Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-3120 in High-Risk Non-muscle Invasive Bladder Cancer
NCT07222488Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Dec 2025
- Primary completion
- Jul 2027
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 12
01
Overview
A Phase 2 trial of MK-3120 in Non-muscle-invasive bladder cancer (NMIBC), sponsored by Merck & Co.. Started Dec 2025; status: recruiting.
02
Drugs
MK-3120
03
Conditions
Non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT07222488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07222488.